Gene Biotherapeutics, Inc.

Equities

CRXM

US8767671048

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:03:37 2024-05-22 am EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2022	Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
2021	Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI

Cardium Therapeutics Inc. Announces Launch Of New MedPodium Neo-Chill Nutra-App(R) at NACDS Marketplace 2012

June 19, 2012 at 09:02 am EDT

Cardium Therapeutics Inc. announced that the Company will introduce its new MedPodium Neo-Chill Nutra-App(R) at the National Association of Chain Drug Stores Marketplace 2012. MedPodium's Neo-Chill Nutra-App(R) contains 200 mg Suntheanine(R), a 100% pure L-theanine amino acid also found in green tea, which clinical studies have shown to promote an alert state of relaxation without drowsiness and to promote mental clarity and focus.

Latest news about Gene Biotherapeutics, Inc.

Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-03-29	CI
Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	21-09-03	CI
Gene Biotherapeutics, Inc. Announces Resignation of Murray H. Hutchison from the Board	21-07-28	CI
Gene Biotherapeutics Inc. Enters into an Agreement with Fujifilm Diosynth Biotechnologies to Manufacture the Generx Angiogenic Gene Therapy Product	21-04-26	CI
Gene Biotherapeutics, Inc. Announces Management Changes	20-05-28	CI
Gene Biotherapeutics, Inc. Appoints James L. Grainer as Chief Financial Officer	20-05-28	CI
Gene Biotherapeutics, Inc. announced that it has received $1.7 million in funding from Nostrum Pharmaceuticals LLC	20-05-21	CI
Gene Biotherapeutics Inc. Announces Retirement of Gerald J. Lewis from its Board of Directors	19-03-20	CI
Gene Biotherapeutics Inc. Enters into an Agreement with the Olaregen Therapeutix Inc	18-09-13	CI
Gene Biotherapeutics Mulls Acquisitions	18-01-08	CI
Taxus Cardium Pharmaceuticals Group Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Application	17-06-13	CI
Taxus Cardium Mulls Acquisitions	17-03-01	CI
Taxus Cardium Pharmaceuticals Group, Inc. Announces Board Retirements	16-12-14	CI
Taxus Cardium Mulls Acquisitions	16-10-27	CI
Taxus Cardium Considers Strategic Alternatives	16-08-29	CI
Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	15-05-21	CI
Taxus Cardium Pharmaceuticals Group Inc. Enters into Binding Term Sheet with Dr. Reddy’S Laboratories Ltd	15-04-09	CI
Dennis Mulroy Resigns as Chief Financial Officer of Taxus Cardium Pharmaceuticals Group Inc on April 3, 2015	15-04-03	CI
TaxuCardium Pharmaceuticals Group Inc. Announces Election of New Directors	15-01-15	CI
Taxus Cardium Pharmaceuticals Group, Inc. announced that it has received $2.289653 million in funding from Taxus Pharmaceuticals, Inc.	14-12-28	CI
TaxuCardium Pharmaceuticals Group Inc. Reports Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014	14-11-20	CI
TaxuCardium Pharmaceuticals Group Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014	14-08-12	CI
Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx(R) Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention	14-06-24	CI
Cardium Therapeutics to Announce Interim Results of Generx Angiogenic Gene Therapy Phase 3 Clinical Study at the 2014 Bio International Convention	14-06-12	CI
TaxuCardium Pharmaceuticals Group Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2014	14-05-15	CI

Chart Gene Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

Gene Biotherapeutics Inc. is a clinical-stage biotechnology company, which is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The technology platform is designed to biologically activate the human body's innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for advanced tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The Generx product candidate is under clinical development, which is cleared by the United States Food and Drug Administration (FDA) for a Phase III clinical study.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENE BIOTHERAPEUTICS, INC.	-.--%	64
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research